The imgt/HLA database

Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK.
Nucleic Acids Research (Impact Factor: 9.11). 11/2010; 39(Database issue):D1171-6. DOI: 10.1093/nar/gkq998
Source: PubMed


It is 12 years since the IMGT/HLA database was first released, providing the HLA community with a searchable repository of highly curated HLA sequences. The HLA complex is located within the 6p21.3 region of human chromosome 6 and contains more than 220 genes of diverse function. Many of the genes encode proteins of the immune system and are highly polymorphic. The naming of these HLA genes and alleles and their quality control is the responsibility of the WHO Nomenclature Committee for Factors of the HLA System. Through the work of the HLA Informatics Group and in collaboration with the European Bioinformatics Institute, we are able to provide public access to this data through the web site Regular updates to the web site ensure that new and confirmatory sequences are dispersed to the HLA community, and the wider research and clinical communities.

Download full-text


Available from: James Robinson,
  • Source
    • "( imgt/hla/probe.html) [28] [29] . Luminex 100 flow analyzer identified HLA alleles via HLA visual 1.0 software by referring to HLA typing template data for DRB1 and DQB1 provided by manufacturer (OneLambda, Inc. "
    [Show description] [Hide description]
    DESCRIPTION: Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease
  • Source
    • "The HLA system allows distinguishing between the biological Self and the Non-Self and is the most polymorphic multi locus system known so far. On an indicative basis, 9000 different alleles were identified in 2013 (Robinson et al., 2013). The HLA encoded proteins (antigens) carried on the cell's surface allow the immune system to recognize them as being foreign or not. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The use of genetic predictive markers in medical practice does not necessarily bear the same kind of medical and ethical consequences than that of genes directly involved in monogenic diseases. However, the French bioethics law framed in the same way the production and use of any genetic information. It seems therefore necessary to explore the practical and ethical context of the actual use of predictive markers in order to highlight their specific stakes. In this study, we document the uses of HLA-B(*)27, which are an interesting example of the multiple features of genetic predictive marker in general medical practice. Materials and methods: The aims of this monocentric and qualitative study were to identify concrete and ethical issues of using the HLA-B(*)27 marker and the interests and limits of the legal framework as perceived by prescribers. In this regard, a thematic and descriptive analysis of five rheumatologists' semi-structured and face-to-face interviews was performed. Results: According to most of the interviewees, HLA-B(*)27 is an "overframed" test because they considered that this test is not really genetic or at least does not have the same nature as "classical genetic tests"; HLA-B(*)27 is not concerned by the ethical challenges of genetic test; the major ethics stake of this marker is not linked to its genetic nature but rather to the complexity of the probabilistic information. This study allows also showing that HLA-B(*)27, validated for a certain usage, may be used in different ways in practice. Discussion: This marker and its clinical uses underline the challenges of translating both statistical concepts and unifying legal framework in clinical practice. This study allows identifying some new aspects and stakes of genetics in medicine and shows the need of additional studies about the use of predictive genetic markers, in order to provide a better basis for decisions and legal framework regarding these practices.
    Frontiers in Genetics 11/2015; 6:299. DOI:10.3389/fgene.2015.00299
  • Source
    • "( imgt/hla/probe.html) [28] [29] . Luminex 100 flow analyzer identified HLA alleles via HLA visual 1.0 software by referring to HLA typing template data for DRB1 and DQB1 provided by manufacturer (OneLambda, Inc. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Alloimmunization or the development of alloantibodies to Red Blood Cell (RBC) antigens is considered one of the major complications after RBC transfusions in patients with sickle cell disease (SCD) and can lead to both acute and delayed hemolytic reactions. It has been suggested that polymorphisms in HLA genes, may play a role in alloimmunization. We conducted a retrospective study analyzing the influence of HLA-DRB1 and DQB1 genetic diversity on RBC-alloimmunization. Study design: Two-hundred four multi-transfused SCD patients with and without RBC-alloimmunization were typed at low/medium resolution by PCR-SSO, using IMGT-HLA Database. HLA-DRB1 and DQB1 allele frequencies were analyzed using logistic regression models, and global p-value was calculated using multiple logistic regression. Results: While only trends towards associations between HLA-DR diversity and alloimmunization were observed, analysis of HLA-DQ showed that HLA-DQ2 (p=0.02), -DQ3 (p=0.02) and -DQ5 (p=0.01) alleles were significantly higher in non-alloimmunized patients, likely behaving as protective alleles. In addition, multiple logistic regression analysis showed both HLA-DQ2/6 (p=0.01) and HLA-DQ5/5 (p=0.03) combinations constitute additional predictor of protective status. Conclusion: Our data suggest that particular HLA-DQ alleles influence the clinical course of RBC transfusion in patients with SCD, which could pave the way towards predictive strategies.
    Human immunology 10/2015; DOI:10.1016/j.humimm.2015.10.010 · 2.14 Impact Factor
Show more